Preston Noon
Direttore/Membro del Consiglio presso ViTToria Biotherapeutics, Inc.
Posizioni attive di Preston Noon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Investitore di Private Equity | - | - |
ViTToria Biotherapeutics, Inc.
 ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Preston Noon
Formazione di Preston Noon
| University of Connecticut | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
Posizioni
| Private Equity Investor | 1 |
| Masters Business Admin | 1 |
| Director/Board Member | 1 |
Settori
| Finance | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
ViTToria Biotherapeutics, Inc.
ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Preston Noon
- Esperienza
